Sex Differences Among Participants in the Latin American Stroke Registry

Antonio Arauz, MD, PhD; Fabiola Serrano, MD, MSc; Sebastián F. Ameriso, MD; Virginia Pujol-Lereis, MD; Alan Flores, MD; Hernán Bayona, MD; Huberth Fernández, MD, MSc; Alejandro Castillo, MD; Rosa Ecos, MD; Jorge Vazquez, MD; Pablo Amaya, MD; Ángelica Ruiz, MD, MSc; Minerva López, MD; Carlos Zapata, MD; Luis Roa, MD; Juan Manuel Marquez-Romero, MD; Eugenia Morelos, MD; Marco A. Ochoa, MD; Carolina Leon, MD; Felipe Romero, MD; José Luis Ruiz-Sandoval, MD; Abraham Reyes, MD; Miguel A. Barboza, MD, MSc; on behalf of the Latin American Stroke Registry*

Background—Reports on sex differences in stroke outcome and risk factors are scarce in Latin America. Our objective was to analyze clinical and prognostic differences according to sex among participants in the LASE (Latin American Stroke Registry).

Methods and Results—Nineteen centers across Central and South America compiled data on demographics, vascular risk factors, clinical stroke description, ancillary tests, and functional outcomes at short-term follow-up of patients included from January 2012 to January 2017. For the present study, all these variables were analyzed according to sex at hospital discharge. We included 4788 patients with a median in-hospital stay of 8 days (interquartile range, 5–8); 2677 were male (median age, 66 years) and 2111 female (median age, 60 years). Ischemic stroke occurred in 4293: 3686 as cerebral infarction (77%) and 607 as transient ischemic attack cases (12.7%); 495 patients (10.3%) corresponded to intracerebral hemorrhage. Poor functional outcome (modified Rankin scale, 3–6) was present in 1662 (34.7%) patients and 38.2% of women (P<0.001). Mortality was present in 6.8% of the registry, with 7.8% in women compared with 6.0% in men (P=0.01). Death and poor functional outcome for all-type stroke showed a higher risk in female patients (hazard ratio, 1.3, P=0.03; and hazard ratio, 1.1, P=0.001, respectively).

Conclusions—A worse functional outcome and higher mortality rates occurred in women compared with men in the LASE, confirming sex differences issues at short-term follow-up. (J Am Heart Assoc. 2020;9:e013903. DOI: 10.1161/JAHA.119.013903.)

Key Words: Latin America • sex • stroke outcome • stroke registry • vascular risk factors

Stroke is the second leading cause of death worldwide, with nearly 5.5 million deaths related to this condition in 2016.1 In the Global Burden of Disease study, stroke subanalysis showed that men and women had similar age-specific incidences at ages up to 55 years, with higher rates in men at 55 to 75 years and a subsequent decrease in patients older than 75 years.2 The overall global sex prevalence in 2016 was 41.1 million women and 39.0 million men.1,2

Sex differences have been reported in stroke registries worldwide3–6 based on risk factors, prevalence, incidence,
Sex Differences in the LASE

Arauz et al

DOI: 10.1161/JAHA.119.013903

Journal of the American Heart Association

Clinical Perspective

What Is New?

• This is the first report addressing sex disparities in post-stroke functional outcomes in Latin America. We documented worse functional outcomes and higher mortality in women.

What Are the Clinical Implications?

• Stroke networks in Latin America should emphasize quality of care in stroke patients, improving in not only scientific knowledge and technology, but also in access to acute stroke care and post-stroke services geared toward reducing the noted sex-based stroke disparities.

Methods

The data sets generated during and/or analyzed during the current study are not publicly available because of each institutional policy but are available from the corresponding author on reasonable request.

The LASE (Latin American Stroke Registry) is an initiative that explores several topics related to functional status in patients following stroke via a multicenter, population-based sample from tertiary hospitals in the region using robust data compilation and methodology. The aim of this study was to analyze the influence of sex on underlying patient characteristics, stroke subtypes, and functional outcome, among participants in the LASE.

Setting and Population

The data sets were prospectively collected from consecutive patients admitted to participating hospitals (study period from January 2012 to January 2017). The inclusion criterion to recruit patients for the present analysis from the data sets was patients with a first stroke as demonstrated by imaging studies. All ischemic strokes (IS), primary intracerebral hemorrhages (ICH), and transient ischemic attack were included, whereas subarachnoid hemorrhage cases were excluded (as the analysis of this condition is done in a separate department in most of the hospitals). Only patients older than 18 years of age were included in the present...
analysis, as most of the hospitals only attend adult cases. We also excluded cases with incomplete in-hospital information that could not be corroborated via medical files. Cerebral venous thrombosis cases were also excluded from the current analysis, as this condition will be analyzed in a separate study.

IS subtype classification was based on the modified Trial of Org 10172 of the Acute Stroke Treatment classification using a consensus approach, and if necessary, modified by the findings of subsequent ancillary diagnostic tests. For the purpose of the present study, the analysis of data was performed on the basis of the acute case; therefore, only in-hospital information was analyzed. Information was collected from the original data sets, but for those missing data we attempted to review all relevant medical records to collect all available information.

**Risk Factors Recorded**

The data set of each center was compiled in a single database by 2 of the authors (FS and MAB). *Baseline characteristics:* age, sex and place of living (rural or urban). *Vascular risk factors and comorbid conditions:* hypertension (defined as previous known,
current treatment, or values ≥140/90 mm Hg in at least 2 subsequent measurements), atrial fibrillation (history of chronic atrial fibrillation, supported by past ECG and positive ECG during hospitalization or past medical history with positive ECG), previous myocardial infarction (previous diagnosis based on a documented transient elevation of biochemical markers of myocardial necrosis with typical ECG signs), transient ischemic attack (defined as an acute neurological deficit of vascular origin lasting <1 hour, with no parenchymal lesions on brain imaging), diabetes mellitus (DM; defined as previous known, concurrent treatment with insulin or oral hypoglycemic medications, or fasting plasma glucose level ≥140 mg/dL), smoking (current or former practice [subject had stopped smoking for at least 2 years preceding the stroke event]), and family history of stroke or acute myocardial infarction.

Paraclinical Assessment

In addition to cerebral computed tomography and/or magnetic resonance imaging, most of the patients received a standardized workup to rule out definite causes of stroke. The workup consisted of routine blood tests and a coagulation study (tests for protein S, protein C, antithrombin III, and antiphospholipid antibodies were performed only in young patients with no other vascular risk factors), 12-lead ECG and echocardiography, and at least 1 of the following vascular studies: digital subtraction angiography, magnetic resonance angiography, computed tomography angiography, and cervical and transcranial Doppler, according to availability at each medical center. The following disorders were considered to be definite causes of IS: large-artery atherosclerosis (defined by a stenosis of at least 50% or occlusion of the corresponding vessel); lacunar stroke (defined by a small, deep infarct 15 mm in diameter in a patient with hypertension); cardioembolic causes, including atrial fibrillation, recent (within 4 months before the stroke) myocardial infarction, dilated cardiomyopathy, rheumatic mitral stenosis, mitral or aortic vegetations or prostheses, left atrial or left ventricular thrombus or tumor, akinetichotdleftventricularsegment, spontaneous echo contrast of the left atrium, and complex atheroma of the aortic arch; and other determined etiologies of stroke, such as nonatherosclerotic arteriopathies (eg, dissection), coagulopathies, and hematologic or systemic disorders (eg, antiphospholipid-antibody syndrome). Cryptogenic stroke was recorded in patients with no likely etiology despite an extensive evaluation. In cases where the cause of a stroke could not be determined with confidence because of insufficient ancillary diagnostic tests, unidentified etiology with incomplete evaluation was recorded; on the other hand, cases with ≥2 possible etiologies or those with disagreement among raters were reviewed by the expert from the stroke clinic at each hospital to determine the most suitable etiology based on all evidence.

Outcome Measures

For the purposes of this analysis, only in-hospital evolution and discharge information was taken into account. Clinical outcome was systematically recorded as measured by the modified Rankin scale at discharge. Poor clinical outcome was defined as a modified Rankin scale 3 to 6, whereas the total mortality in this period of time was analyzed in spite of the death considered or not related to the index stroke.

Statistical Analysis

We compared female and male patients (as the dependent variable) using chi-squared test or Fisher’s exact test for dichotomous data (vascular risk factors, demographics, type of stroke, functional outcome, and age groups), and the Mann–Whitney U or Student t test for continuous data, according to normality tests on continuous variables (age or length of in hospital stay). Mean and SD for normally distributed variables, as median and interquartile range for not normally distributed variables are also provided. Potential predictor factors (vascular risk factors, age groups, severity of the infarction [according to National Institutes of Health stroke scale] and acute therapy intervention [intravenous thrombolysis, thrombectomy, and stroke unit admission]) of death and poor functional outcome (modified Rankin scale, 3–6) by sex were selected on the basis of clinical plausibility, and separate univariate analysis for each risk factor; those with P<0.1 were entered in a stepwise forward regression model, adjusting for age. Stratified analysis for sex in terms of death and poor functional outcome was performed. The Hosmer–Lemeshow goodness-of-fit test was used in logistic regression models when analyzing covariate influence.

Multivariate Cox regression analysis was performed to compare sex by functional outcome and death (adjusted for age groups, vascular risk factors, type and severity of stroke [National Institutes of Health stroke scale score grouped into mild, moderate, or severe]). Kaplan–Meier survival curves were used to assess the absolute risk of recurrent cerebrovascular events in the acute period (in-hospital). Significance was defined as P<0.05. Odds ratios (ORs), hazard ratios (HRs), and 95% CIs were calculated. All statistical analyses were performed using the SPSS 22.0 package (SPSS Statistics for Windows, IBM Corp., Armonk, NY).

Results

Patients and Demographics

We recruited and registered data from 5336 patients: 275 (5.1%) of these patients were excluded because of the absence
of complete information in their medical records and were not reachable, 40 (0.7%) subjects were excluded because of lack of initial neuroimaging, 48 (1%) patients were not included in the present study because of a diagnosis of cerebral venous thrombosis, and 185 (3.4%) were excluded because of incomplete data regarding stroke subtype etiology. Accordingly, only 4788 patients with an imaging-confirmed first stroke and with complete inpatient clinical information were included in the analysis. Patients had a median in-hospital stay of 8 days (interquartile range, 5–8), which was similar in men and women. Detailed information according to each country and center, can be found in Tables S1 and S2.

There were 2677 males (median age, 66 years; interquartile range, 56–77) and 2111 females (median age, 69 years; interquartile range, 56–80). IS occurred in 4293 patients: 3686 as cerebral infarction (77%) and 607 as a transient ischemic attack cases (12.7%); 495 patients (10.3%) corresponded to ICH; see Table 1.

### Table 1. General Features and Vascular Risk Factors

|                      | Men N=2677 (%) | Women N=2111 (%) | Total N=4788 (%) | P Value |
|----------------------|----------------|------------------|------------------|---------|
| **Age, y**           | 66 (56–77)     | 69 (56–80)       | 67 (55–78)       | 0.06†   |
| **Hospital stay, d** | 7 (3–8)        | 7 (4–8)          | 8 (5–8)          | 0.15†   |
| **Risk factors**     |                |                  |                  |         |
| Hypertension         | 1618 (60.4)    | 1286 (60.9)      | 2904 (60.7)      | 0.93    |
| Diabetes mellitus    | 662 (24.7)     | 530 (25.1)       | 1192 (24.9)      | 0.88    |
| Current smoking      | 492 (18.4)     | 252 (11.9)       | 744 (15.5)       | <0.001  |
| Coronary disease     | 256 (9.6)      | 135 (6.4)        | 391 (8.2)        | <0.001  |
| Hypercholesterolemia | 697 (26.0)     | 496 (23.5)       | 1193 (24.9)      | 0.02    |
| Known atrial fibrillation | 247 (9.2) | 168 (8.0) | 415 (8.7) | 0.1 |
| **Type of stroke**   |                |                  |                  |         |
| Ischemic             | 2068 (77.3)    | 1618 (76.6)      | 3686 (77)        | 0.23    |
| Intracerebral hemorrhage | 285 (10.6)  | 210 (9.9)        | 495 (10.3)       | 0.35    |
| Transient ischemic attack | 324 (12.1) | 283 (13.4)       | 607 (12.7)       | 0.23    |
| National Institutes of Health stroke scale (admission)* | 7 (3–15) | 8 (4–16) | 8 (4–15) | 0.01† |
| **Acute management (ischemic stroke)** | | | | |
| Intravenous thrombolysis | 197 (7.4)  | 192 (9.1) | 389 (8.1) | 0.03 |
| Thrombectomy         | 19 (0.7)       | 17 (0.8)         | 36 (0.8)         | 0.70    |
| Stroke unit          | 1710 (63.9)    | 1293 (61.3)      | 3003 (62.7)      | 0.06    |
| **Etiology of ischemic stroke (Trial of Org 10172 of the Acute Stroke Treatment)** | | | | 0.24 |
| Atherosclerotic      | 524 (25.4)     | 376 (23.3)       | 900 (24.4)       |         |
| Cardioembolic        | 464 (22.4)     | 380 (23.5)       | 844 (22.9)       |         |
| Small-vessel disease | 193 (9.3)      | 157 (9.7)        | 350 (9.5)        |         |
| Other etiologies     | 135 (6.5)      | 120 (7.4)        | 255 (6.9)        |         |
| Cryptogenic          | 214 (10.4)     | 178 (11.0)       | 396 (11.0)       |         |
| Incomplete evaluation| 526 (25.4)     | 404 (25.0)       | 930 (25.5)       |         |
| **Functional outcome (discharge)** | | | | |
| Poor functional outcome (modified Rankin scale 3–6) | 859 (31.9) | 811 (37.8) | 1670 (34.5) | <0.001 |
| Death                | 161 (6.0)      | 165 (7.7)        | 326 (6.7)        | 0.02    |

*Median (interquartile range).  
†P value by Mann–Whitney U Wilcoxon test.
Vascular Risk Factors by Sex

No significant differences were found among men and women on the frequency of hypertension (OR, 0.9; 95% CI, 0.8–1.1; P=0.93) and DM (OR, 1.0; 95% CI, 0.8–1.1; P=0.88), which was 60.7% and 24.9%, respectively, in the entire data set. Current smoking (OR, 1.3; 95% CI, 0.5–0.7; P<0.001), hypercholesterolemia (OR, 1.1; 95% CI, 1.0–1.2; P=0.02), and coronary disease (OR, 1.4; 95% CI, 0.5–0.9; P<0.001) were significantly more frequent in men. In terms of transient ischemic attack, no significant differences were found for vascular risk factors among men and women.

Stroke Etiology by Sex

IS cases according to the Trial of Org 10172 of the Acute Stroke Treatment classification were as follows: atherothrombotic, 24.4%; cardioembolic, 22.9%; small-vessel disease, 9.5%; other determined etiology, 6.9%; cryptogenic, 11%; and unidentified etiology with incomplete evaluation, 25.5%. No differences were found among men and women by IS subtype (see Table 1).

In terms of ICH, the most common location was the basal ganglia. Of all cases, 75.4% were associated with hypertension, 5.9% with arteriovenous malformations, 4% were related to nonaneurysmal subarachnoid hemorrhage, 3.8% to amyloid angiopathy, 2.8% to drugs (antiplatelet/anticoagulants), and 7.7% were undetermined because of incomplete studies. No differences were detected among men and women according to ICH etiology. Hypertensive ICH presented with 202 (40.8%) patients who were taking antihypertensive medication irregularly or had suspended their usage; 76 (15.4%) patients did not know they had hypertension.

Table 2. Unadjusted Odds Ratio for Major Risk Factors and Subtype of Stroke by Outcome (Poor Functional Outcome and Death)

| Risk factors            | Modified Rankin Scale 3–6 | Death                  |
|-------------------------|---------------------------|------------------------|
|                         | Women (OR [95% CI]) | P Value | Men (OR [95% CI]) | P Value | Women (OR [95% CI]) | P Value | Men (OR [95% CI]) | P Value |
| Hypertension            | 2.2 (1.8–2.6)           | <0.001 | 1.5 (1.3–1.8)    | <0.001 | 1.6 (1.1–2.2)     | 0.009  | 1.6 (1.1–2.2)     | 0.008   |
| Diabetes mellitus       | 1.7 (1.4–2.1)           | <0.001 | 1.4 (1.1–1.6)    | <0.001 | 1.2 (0.8–1.7)     | 2.53   | 1.1 (0.8–1.6)     | 0.40    |
| Current smoking         | 1.1 (0.8–1.5)           | 0.28   | 1.8 (1.5–2.3)    | <0.001 | 1.2 (0.7–1.9)     | 0.36   | 1.4 (0.9–2.0)     | 0.08    |
| Dyslipidemia            | 0.8 (0.7–1.1)           | 0.17   | 0.6 (0.5–0.8)    | <0.001 | 0.9 (0.6–1.3)     | 0.92   | 0.6 (0.4–0.9)     | 0.02    |
| Stroke subtype          |                          |         |                    |         |                    |         |                    |         |
| Ischemic                | 2.9 (2.3–3.7)           | <0.001 | 2.4 (1.9–3.1)    | <0.001 | 1.6 (1.0–2.4)     | 0.03   | 1.1 (0.7–1.6)     | 0.66    |
| Intracerebral hemorrhage| 1.7 (1.3–2.3)           | <0.001 | 1.3 (1.1–1.7)    | 0.01   | 2.0 (1.3–3.1)     | 0.001  | 2.4 (1.6–3.6)     | <0.001  |

OR indicates odds ratio.

In-Hospital Functional Outcome by Sex

Overall, poor functional outcome was present in 1662 (34.7%) patients, with 38.2% of women having this condition (OR, 1.3; 95% CI, 1.2–1.5; P<0.001) and 31.9% in male patients (OR, 1.1; 95% CI, 1.0–1.2; P=0.001). Mortality was present in 6.8% of the registry, with 7.8% in women compared with 6.0% in men (OR, 1.3; 95% CI, 1.0–1.6; P=0.02).

Acute management did not influence poor functional outcome by sex, according to those admitted to a stroke unit (male, 47% versus female, 48.7%; P=0.49), received intravenous thrombolysis (male, 12.5% versus female, 12.5%; P=0.9), or acute thrombectomy (male, 1.9% versus female, 1.2%; P=0.30); findings were the same in terms of mortality by sex for male versus female for stroke unit (P=0.9), intravenous thrombolysis (P=0.17), and acute thrombectomy (P=0.49). When the composite of “any acute reperfusion therapy” was analyzed by sex for each country, no significant difference was found.

By stroke subtype, the worst functional prognosis, including the highest mortality, corresponded to ICH patients: 43.2% with modified Rankin scale 3 to 6 (214 ICH patients: female cases, 50% versus 38.5% in male patients; P=0.009), of which 62 (12.5%) patients died (female cases, 13.3% versus 11.9% in male patients; P=0.64). Table 2 depicts the OR for major risk factors and subtype of stroke by functional outcome. Overall, female IS presented with the highest poor clinical outcome (OR, 2.9; 95% CI, 1.9–3.1; P<0.001) compared with male cases (OR, 2.4; 95% CI, 1.9–3.1; P=0.001). On the other hand, the highest risk of death was seen in male ICH patients (OR, 2.0; 95% CI, 1.3–3.1; P=0.001).

Unadjusted and adjusted Cox proportional hazard models (adjusted for age groups, risk factors, and type of stroke)
Sex Differences in the LASE  Arauz et al

### Table 3. Cox Proportional Hazard Ratios Analysis for Clinical Outcome at Discharge According to Sex

| Outcome                     | Men (%) | Women (%) | Unadjusted       | Adjusted*        |
|-----------------------------|---------|-----------|------------------|------------------|
|                             | HR (95% CI) | P Value | HR (95% CI) | P Value |
| All-type stroke             |         |          |                 |                  |
| Death                       | 161 (6.0) | 165 (7.7) | 1.3 (1.0–1.6)   | 0.02             |
| Modified Rankin scale 3–6   | 859 (31.9) | 811 (37.8) | 1.2 (1.1–1.3)   | <0.001           |
| Ischemic stroke             |         |          |                 |                  |
| Death                       | 126 (6.1) | 136 (8.4) | 1.3 (1.0–1.7)   | 0.01             |
| mRs 3–6                     | 744 (36.0) | 702 (43.4) | 1.2 (1.0–1.3)   | 0.002            |
| Intracerebral hemorrhage    |         |          |                 |                  |
| Death                       | 34 (11.9) | 28 (13.3) | 1.1 (0.7–1.9)   | 0.58             |
| Modified Rankin scale 3–6   | 109 (38.2) | 105 (50.0) | 1.3 (1.0–1.7)   | 0.03             |

HR indicates hazard ratios.
*Adjusted for age, vascular risk factors, National Institutes of Health stroke scale score (dichotomized), etiology (for ischemic stroke), and acute management (reperfusion therapy for ischemic stroke).

Discussion

In this study, we found worse functional outcome and higher mortality among women. In addition, our study shows major findings on the initial severity and outcome, where women had higher initial National Institutes of Health stroke scale score, tended to be younger, and presented with a poorer outcome at discharge. This is concordant with data from other, similar reports. In many countries, the total burden of disease attributed to stroke is greater in women than in men. Women have been reported to have worse outcome, including greater mortality, worse functional outcome, and poorer health-related quality of life versus men. A meta-analysis of population-based studies found that stroke tended to be...
| Functional Outcome | <50 years (N=800) | 50–60 years (N=831) | 61–70 years (N=1245) | 71–80 years (N=1049) | >80 years (N=911) |
|--------------------|------------------|-------------------|---------------------|---------------------|------------------|
|                    | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Modified Rankin scale 3–6 | n=229 | 1.0 (0.8–1.4) | 0.66 | 1.2 (0.9–1.6) | 0.08 | 1.2 (1.0–1.5) | 0.06 | 1.3 (1.1–1.6) | 0.004 | 0.9 (0.8–1.2) | 0.85 |
| Sex | n=273 | 1.2 (0.8–1.5) | 0.23 | 0.9 (0.7–1.3) | 0.90 | 1.3 (1.1–2.1) | <0.001 | 1.7 (1.3–2.3) | <0.001 | 1.5 (1.2–1.9) | 0.001 |
| Hypertension | n=387 | 1.5 (1.0–2.1) | 0.04 | 1.2 (0.9–1.6) | 0.18 | 1.3 (1.0–1.6) | 0.01 | 1.1 (0.8–1.4) | 0.33 | 1.3 (1.0–1.6) | 0.02 |
| Diabetes mellitus | n=358 | 1.4 (1.0–1.9) | 0.08 | 1.1 (0.8–1.5) | 0.39 | 1.3 (1.0–1.7) | 0.03 | 1.1 (0.8–1.4) | 0.47 | 0.8 (0.6–1.0) | 0.11 |
| Smoking | n=42 | 0.7 (0.4–1.2) | 0.09 | 0.9 (0.7–1.2) | 0.73 | 0.7 (0.6–0.9) | 0.009 | 0.7 (0.5–0.9) | 0.05 | 0.9 (0.7–1.2) | 0.74 |
| Hypercholesterolemia | n=42 | 0.8 (0.5–1.7) | 0.77 | 2.2 (1.1–4.2) | 0.01 | 1.2 (0.7–1.8) | 0.40 | 1.3 (0.8–2.2) | 0.22 | 1.1 (0.7–1.6) | 0.72 |
| Death | n=42 | 0.9 (0.3–1.8) | 0.56 | 1.4 (0.6–2.8) | 0.78 | 1.3 (0.8–2.3) | 0.25 | 1.5 (0.9–2.9) | 0.17 | 1.5 (0.9–2.5) | 0.08 |
| Sex | n=61 | 0.6 (1.5–2.6) | 0.51 | 1.1 (0.5–2.1) | 0.03 | 1.7 (1.0–2.7) | 0.03 | 1.1 (0.6–2.0) | 0.58 | 0.7 (0.4–1.2) | 0.26 |
| Hypertension | n=61 | 1.1 (0.4–2.6) | 0.76 | 1.1 (0.5–2.3) | 0.63 | 1.5 (0.9–2.5) | 0.10 | 1.4 (0.8–2.7) | 0.23 | 0.6 (0.3–1.1) | 0.10 |
| Diabetes mellitus | n=102 | 0.1 (0.1–ND) | 0.90 | 1.0 (0.5–2.2) | 0.57 | 0.7 (0.4–1.1) | 0.12 | 0.6 (0.3–1.1) | 0.11 | 0.8 (0.5–1.4) | 0.61 |

HR indicates hazard ratio.

*Adjusted for vascular risk factors, National Institutes of Health stroke scale score (dichotomized), etiology (for ischemic stroke), and acute management (reperfusion therapy for ischemic stroke).
Similar findings have been reported in case-control studies when comparing risk factors by sex for stroke occurrence, with the highest association for hypertension, DM, dyslipidemia, and stress in the preceding 2 weeks of stroke as well as low consumption of green leafy vegetables.\textsuperscript{18}

In terms of clinical outcome of stroke, differences according to sex have been explained according to sexual dimorphism in response to drugs (distribution volumes, sex hormone levels, activity of enzymes, and effects of routes of excretion)\textsuperscript{19} but also stroke cases in women with older ages (attributable to the higher lifetime risk and life expectancy),\textsuperscript{7} which have been reported with the age cutoff of \( \geq 75 \) years (as seen in our study)\textsuperscript{20} and possibly reflecting compounding disability in the older age range. In addition, accessibility to healthcare centers has been postulated as an explanatory or additional condition for this functional outcome: In some registries, women were less likely to present to a medical facility in the acute stroke window compared with men.\textsuperscript{21} In general, cardiovascular disease, behavioral health, and access to care are problem areas for women that require immediate attention.\textsuperscript{22}

When analyzing healthcare access and quality of medical services in Latin America according to the Healthcare Access and Quality Index from the Global Burden of Disease Study,\textsuperscript{23} most Latin American countries scored between the fourth and sixth deciles of the index, indicating an intermediate access to medical services. However, when looking at subnational patterns, Mexico presented with the highest healthcare access inequalities across the states for our region.\textsuperscript{23} This observation regarding the medical services across the region could also explain the aforementioned disparate access for women, especially in areas where hospitals, primary attention clinics, medication, and imaging studies availability are more limited.\textsuperscript{24,25} In Latin America, the management of stroke patients differs substantially from other regions of the world, especially compared with developed countries.\textsuperscript{26} There are substantial problems with the acute phase of stroke treatment: Despite the fact that there are some stroke units, these are available in only a few countries, and their number varies substantially. Given that stroke management is a continuum that begins with the treatment in the acute phase, sex-related factors may be important throughout the entire care process.

Certain study limitations should be acknowledged. First, as this is a retrospective analysis from a multicenter merged database, the study presents the bias of an observational study despite efforts to maintain strict and methodical variable analysis and the sole inclusion of matching information suitable for the analysis. Second, most of the centers represent a tertiary healthcare facility, which could cause an overrepresentation of stroke frequency and not accurately represent the reality of this condition in the entire country, especially because of the access of studies that determined stroke etiology compared with hospitals with less infrastructure or paraclinical access. Furthermore, Latin American regions present differences in every country, and many countries and latitudes are not represented in our analysis; the lack of stroke units (as a formal structure for stroke care) is evident in our registry, which also leads to a difficulty when comparing different centers in our region.\textsuperscript{26} Third, association analysis on the basis of covariate adjustment could disregard other variables when explaining the influence of sex on stroke outcome and could overrepresent the magnitude of the effect, especially when comparing accessibility to medical services in every region, therapeutic approaches, and postdischarge medical and rehabilitation attention. Fourth, findings for IS and ICH were relatively similar according to sex. However, a weakness of our registry is the exclusion of cases of subarachnoid hemorrhage, which was reportedly significantly higher in women in other studies.\textsuperscript{5}

## Conclusions

In the LASE, worse functional outcome and death rates were present in women compared with men. These findings should be considered in Latin America and Hispanic populations abroad when designing and implementing individual management plans for stroke patients, along with secondary prevention and neuro-rehabilitation programs.

## Appendix

### Co-Investigators and Collaborators of the LASE

Ana M. Valencia-Chávez, MD; María P. Rosa Calle-La, MD; Carlos Abanto-Argomedo, MD; Larry Benavides-Vásquez, MD; Ricardo Otiniano-Sinfuentes, MD (Neurology Department, Instituto Nacional de Ciencias Neurológicas, Lima, Perú). Ricardo Mernes, MD; Christian Otto, MD (Neurology Department, Facultad de Ciencias Medicas, Universidad Nacional de Asunción, Paraguay). Jaime Valderrama, MD (Neurology Department Fundación Clínica Valle del Lili, Cali, Colombia). Carlos F. Martínez, MD; Jaime E. Rodríguez, MD; Brenda V. Roperro, MD (Stroke Center, Neurology Department, Hospital Universitario Fundación Santa Fe de Bogotá, Colombia). German López-Valencia, MD (Neurology Department Hospital Civil Fray Antonio Alcada, Guadalajara, Jalisco, México). Eduardo Soriano, MD; Rodrigo Gonzalez-Oscoy, MD; Carmen Arteaga, MD; Beatriz Mendez, MD; Cristina Ramos, MD (Stroke Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez, México City, México). Gabriel Torrealba, MD (Neurosciences Department Hospital Dr. Rafael Calderón Guardia (CCSS), San José, Costa Rica).
Disclosures
None.

References
1. Gorelick PB. The global burden of stroke: persistent and disabling. Lancet Neurol. 2019;18:417–418.

2. GBD 2016 Stroke Collaborators. Global, regional and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439–458.

3. Yan S, Gan Y, Li L, Jiang H, Song F, Yin X, Chen L, Fu W, Wang X, Li W, Shu C, Hu S, Wang C, Yue W, Yan F, Wang L, Lv C, Wang Z, Lu Z. Sex differences in risk factors for stroke: a nationwide survey of 700,000 Chinese adults. Eur J Prev Cardiol. 2019 Mar 1;2047487319831483. DOI: 10.1177/2047487319831483. [Epub ahead of print].

4. Giralt D, Domingues-Montanari S, Mendioroz M, Ortega L, Maisterra O, Perea-Medina D, Dominguez-Montanari S, Giuli MT, Blasco A, Estrella PM, et al. Sex differences in stroke: a systematic review and meta-analysis. Acta Neurol Scand. 2012;125:83–90.

5. Appelros P, Stegmayr B, Terent A. The gender gap in stroke: a meta-analysis. Acta Neurol Scand. 2015;132:275–289.

6. Touze E, Rothwell PM. Sex differences in heritability of ischemic stroke: a systematic review and meta-analysis. Stroke. 2008;39:16–23.

7. Yu C, An Z, Zhao W, Wang W, Gao C, Lui S, Wang J, Wu J. Sex differences in stroke subtypes, severity, risk factors, and outcomes among elderly patients with acute ischemic stroke. Front Aging Neurosci. 2015;7:174.

8. Kapral M, Fang J, Hill M, Silver F, Richards J, Jaigobin C, Cheung AM; Canadian Stroke Network. Sex differences in stroke care and outcomes: results from the registry of the Canadian Stroke Network. Stroke. 2005;36:809–814.

9. GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379:2429–2437.

10. Niewada M, Kobayashi A, Sandlerock PA, Kaminbski B, Czonkowska A; International Stroke Trial Collaborative Group. Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischemic stroke in the international stroke trial. Neuropediatrics. 2005;24:123–128.

11. Maeda K, Toyoda K, Minematsu K, Kobayashi S; Japan Standard Stroke Registry Study Group. Effects of sex difference on clinical features of acute ischemic stroke in Japan. J Stroke Cerebrovasc Dis. 2015;22:1070–1075.

12. Barker-Collo S, Bennett DA, Krishnamurthi RV, Parmar P, Feigin VL, Naghavi M, Forouzanfar MH, Jonhson CO, Nguyen G, Mensah GA, Vos T, Murray CJ, Roth GA; GBD 2013 Writing Group; GBD 2013 Stroke Panel Experts Group. Sex differences in stroke incidence, prevalence, mortality and disability-adjusted life years: results from the Global Burden of Disease Study 2013. Neuroepidemiology. 2015;45:203–214.

13. Phan HT, Reeves MJ, Blizzard CL, Thrift AG, Cadilhac DA, Sturm J, Otahal P, Rothwell P, Bejot Y, Cabral NL, Appelros P, Koev J, Vibo R, Minelli C, Gall SL. Sex differences in severity of stroke in the INSTRUCT study: a meta-analysis of individual participant data. J Am Heart Assoc. 2019;8:e0110235. DOI: 10.1161/JAHA.118.010235.

14. Phan HT, Gall SL, Blizzard CL, Lannin NA, Thrift AG, Anderson CS, Kim J, Grimley R, Castley HC, Hand P, Cadilhac DA. Sex differences in care and long-term mortality after stroke: Australian stroke clinical registry. J Womens Health. 2019;28:712–720.

15. Reeves MJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH; Get with the Guidelines-Stroke Steering Committee & Investigators. Quality of care in women with ischemic stroke in the GWTG program. Stroke. 2009;40:1127–1133.

16. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, Mensah GA, Norrving B, Shuie I, Ng M, Esteve K, Cercy K, Murray CJL, Forouzanfar MH; Global Burden of Diseases, Injuries and Risk Factors Study 2013 and Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016;15:913–924.

17. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, McQuenne MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, Avezum A, Mondo C, Diener HC, Rygiewicz D, Czonkowska A, Pogosova N, Weimar C, Iqbal R, Diaz R, Yusoff K, Yusufall A, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogumnuiyi A, Iwenra HK, Malaga G, Rumboldt Z, Oveisgharan A, Al Hussain F, Magazi D, Nialanot Y, Ferguson J, Pare G, Yusuf S; INTERSTROKE investigators. Risk factors for ischemic and intracerebral haemorrhage stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–123.

18. Akpalu A, Gebregziabher M, Oviabiele B, Sarfo F, Jheonye H, Akinyemi R, Akpa O, Tiwari HK, Arnett D, Wahab K, Lackland DB, Abiodun A, Ogbole C, Jenkins C, Arulogun O, Akpalu J, Obiako R, Olowoyo P, Fawale M, Karolame F, Osagibovbo O, Obiabo Y, Chukwuonye I, Owoibi P, Summonu T, Owolabi M. Differential impact of risk factors on stroke occurrence among men versus women in Africa: the SIREN study. Stroke. 2019;50:820–827.

19. Legato MK, Johnson PA, Mansen JE. Consideration of sex differences in medicine to improve health care and patient outcomes. JAMA. 2016;316:1865–1866.

20. Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatwoda A, Lisabeth L. Sex differences in stroke: epidemiology, clinical presentation, medical care and outcomes. Lancet Neurol. 2008;7:915–926.

21. Mehndiratta P, Wasay M, Mehndiratta MM. Implications of female sex on stroke risk factors, care, outcome and rehabilitation: an Asian perspective. Cerebrovasc Dis. 2015;39:302–308.

22. Moore JE, Mompe A, Moe Y. Disparities by sex tracked in the 2015 national healthcare quality and disparities report: trends across national quality strategy priorities, health conditions, and access measures. Womens Health Issues. 2018;28:97–103.

23. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391:2236–2271.

24. Stephens P, Ross-Degman D, Wagner AK. Does access to medicines differ by gender? Evidence from 15 low and middle income countries. Health Policy. 2013;110:60–66.

25. Manuel JI. Racial/ethnic and gender disparities in healthcare use and access. Health Serv Res. 2018;53:1407–1429.

26. Ouriques Martins SC, Sacks C, Hacke W, Brainin M, de Assis Figueredo F, Marques Pontes-Neto O, Lavados Germain PM, Marinho MF, Hoppe Wiegner A, Vacca McGie D, Cruz-Flores S, Ameriso SF, Camargo Villareal WM, Durán JC, Fogolin Passos E, Gomes Neugera R, Freitas de Carvalho J, Sampayo Silva GB, Cabral M, Oliveira-Filho J, Gagliardi R, Gomes de Sousa E, Fagundes Soares F, de Pinho Campos K, Piza Teixeira PF, Goncalves F, Cabral Moro CH, Oliveira-Filho J, Gagliardi R, Gomes de Sousa ED, Fagundes Soares F, de Pinho Campos K, Piza Teixeira PF, Gonçalves IP, Santos Carquin J, Perez Romero GE, Maldonado Figureiro J, Barboza MA, Célis López MA, Góngora-Rivera F, Cantú-Brito C, Novarro-Escudero N, Velázquez Blanco MA, Árbo Oze de Morval CA, Olmedo Bareiro AB, Meza Rojas G, Flores A, Hancoo-Saavedra JA, Pérez Jimenez V, Abanto Argomedo C, Rodríguez Kadota L, Cosa R, Mora Cuervo DL, de Souza AC, Carbonera LA, Alvarez Guzmán TF, Maldonado N, Cabral NL, Anderson C, Lindsay P, Hennis A, Feigin VL. Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurol. 2019;18:674–683.
SUPPLEMENTAL MATERIAL
Table S1. Demographic and clinical characteristics by country.

| Country       | Mexico N=1229 (%) | Argentina N=1252 (%) | Colombia N=821 (%) | Costa Rica N=713 (%) | Paraguay N=532 (%) | Peru N=210 (%) | Ecuador N=31 (%) |
|---------------|-------------------|----------------------|-------------------|----------------------|-------------------|----------------|-----------------|
|                | Men               | Women                | Age, median (IQR) | Risk factors         | Type of stroke    | Acute treatment (ischemic stroke) | Functional status (at discharge) |
|                |                   |                      |                   |                      |                   | IV thrombolysis | Mechanical thrombectomy | |
|                | 668 (54.4) 676 (60.9) | 420 (51.2) 370 (51.9) | 316 (59.4) 126 (60.0) | Hypertension 756 (61.5) 492 (39.3) 547 (66.6) 553 (77.6) 410 (77.1) 123 (58.6) 23 (74.2) | Ischemic 1042 (84.8) 888 (70.9) 582 (70.9) 579 (81.2) 402 (75.6) 170 (81.0) 23 (74.2) | 49 (5.7) -* 82 (10.2) 208 (29.2) -* 23 (12.4) 0 (0) | 3 (0.3) -* 33 (4.1) 2 (0.3) -* 0 (0) 0 (0) |
| Good functional outcome (mRs 0-2) | 577  (46.9) | 1135 (90.7) | 514 (62.6) | 352  (49.4) | 422 (79.3) | 116 (55.2) | 10  (32.3) |
|----------------------------------|-------------|-------------|------------|-------------|------------|------------|-----------|
| Death                            | 124 (10.1)  | 22 (1.8)    | 102 (12.4) | 32 (4.5)    | 37 (7.0)   | 7  (3.3)   | 0  (0)    |
| Recurrence                       |             |             |            |             |            |            |           |
| Ischemic                         | 43  (2.7)   | *           | *          | *           | 24 (4.5)   | 11 (5.3)   | 5  (15.1) |
| Hemorrhagic                      | 1  (0.1)    | *           | *          | *           | 0  (0)     | 1  (0.5)   | 3  (9.7)  |

* Not available at the dataset.
Table S2. Demographic and clinical characteristics by center.

|                     | Center N (%) |
|---------------------|--------------|
|                     | INN N, Mexico City | PEME X, Mexico City | Hospital Juarez, Mexico City | Hospital General, Mexico City | Hospital General, Durango | PEME X, Ciudad Madero | ISSSTE E, Morelia | Hospital Civil, Guadalajara | ISSSTE, Guadalajara |
| **Men**             | 162 (50.9) | 20 (100) | 93 (56.4) | 88 (52.4) | 133 (55.0) | 110 (55.0) | 22 (47.8) | 19 (63.3) | 21 (52.5) |
| **Women**           | 156 (49.1) | 0 (0) | 72 (43.6) | 80 (47.6) | 109 (45.0) | 90 (45.0) | 24 (52.2) | 11 (36.7) | 19 (47.5) |
| **Age, median (IQR)** | 57 (39-68) | 72 (68-81) | 56 (45-66) | 62 (54-70) | 71 (63-81) | 77 (68-83) | 63 (56-76) | 62 (56-70) | 69 (62-75) |
| **Risk factors**    |              |              |              |              |              |              |              |              |              |
| Hypertension        | 127 (39.9) | 86 (52.1) | 112 (66.7) | 206 (85.1) | 153 (76.5) | 31 (67.4) | 17 (56.7) | 24 (60.0) |
| Diabetes            | 68 (21.4) | 52 (31.5) | 76 (45.2) | 103 (42.6) | 116 (58.0) | 25 (54.3) | 12 (40.0) | 17 (42.5) |
| Active Smoking      | 51 (16.0) | 33 (20.0) | 60 (35.7) | 36 (14.9) | 38 (19.0) | 7 (15.2) | 7 (23.3) | 20 (50.0) |
| Hypercholesterolemia| 30 (9.4) | 2 (1.2) | 23 (13.7) | 12 (5.0) | 112 (56.0) | 4 (8.7) | 3 (10.0) | 11 (27.5) |
| **Type of stroke**  |              |              |              |              |              |              |              |              |
| Ischemic            | 291 (91.5) | 149 (90.3) | 168 (100) | 202 (83.5) | 119 (59.5) | 33 (71.7) | 30 (100) | 40 (100) |
| TIA                 | 9 (2.8) | 7 (35.0) | 0 (0) | 0 (0) | 17 (7.0) | 61 (30.5) | 1 (2.2) | 0 (0) | 0 (0) |
| Hemorrhagic         | 18 (3.6) | 3 (15.0) | 16 (9.7) | 0 (0) | 23 (9.5) | 20 (10.0) | 12 (26.1) | 0 (0) | 0 (0) |
| Acute treatment (ischemic stroke) |              |              |              |              |              |              |              |              |


| IV thrombolysis   | -* | 3 (15.0) | 5 (3.4) | 18 (10.7) | 3 (1.2) | 0 (0) | 0 (0) | 0 (0) | 20 (50.0) |
|-------------------|----|---------|---------|-----------|---------|-------|-------|-------|-----------|
| Mechanical        | -* | 0 (0)   | 1 (0.7) | 2 (1.2)   | 0 (0)   | 0 (0) | 0 (0) | 0 (0) | 0 (0)     |
| thrombectomy      |     |         |         |           |         |       |       |       |           |
| **Functional      |     |         |         |           |         |       |       |       |           |
| status (at        |     |         |         |           |         |       |       |       |           |
| discharge)        |     |         |         |           |         |       |       |       |           |
| Good functional   | 195 | 20 (100)| 53 (32.1)| 34 (20.2)  | 85 (35.1)| 132 (66.0)| 16 (34.8)| 14 (46.7)| 28 (70.0) |
| outcome (mRs 0-2) |     |         |         |           |         |       |       |       |           |
| Death             | 0 (0) | 0 (0)   | 2 (1.2) | 19 (11.3)  | 74 (30.6)| 27 (13.5)| 0 (0)  | 0 (0)  | 2 (5.0)   |
| **Recurrence**    |     |         |         |           |         |       |       |       |           |
| Ischemic          | 0 (0) | 0 (0)   | 12 (7.3) | 8 (4.8)   | 8 (3.3) | 3 (0.6) | 1 (2.2) | 1 (3.3) | 0 (0)     |
| Hemorrhagic       | 0 (0) | 0 (0)   | 0 (0)   | 0 (0)     | 0 (0)  | 0 (0)  | 0 (0)  | 1 (3.3) | 0 (0)     |
| Center       | Colombia | Perú | Argentina | Ecuador | Paraguay | Costa Rica |
|--------------|----------|------|-----------|---------|----------|------------|
|              | UFSF, Bogotá | HUM M, Bogotá | Vallec del Lili, Cali | HGGAI, Lima | INCN, Lima | FLENI, Buenos Aires | HPAS, Quito | UNA, Asunción | HRAC G, San José |
| Men          | 262 (51.8) | 60 (42.6) | 98 (56.3) | 82 (58.2) | 44 (63.8) | 762 (60.9) | 15 (48.4) | 316 (59.4) | 370 (51.9) |
| Women        | 244 (48.2) | 81 (57.4) | 76 (43.7) | 59 (41.8) | 25 (36.2) | 490 (39.1) | 16 (51.6) | 216 (40.6) | 343 (48.1) |
| Age, median (IQR) | 73 (61-84) | 75 (64-83) | 68 (58-78) | 67 (54-77) | 71 (56-80) | 67 (59-77) | 61 (48-74) | 62 (53-73) | 67 (56-79) |
| Risk factors |          |      |          |         |          |            |          |            |            |
| Hypertension | 331 (65.4) | 97 (68.8) | 119 (68.4) | 73 (51.8) | 70 (72.5) | 492 (39.3) | 23 (74.2) | 410 (77.1) | 553 (77.6) |
| Diabetes     | 101 (20.0) | 18 (12.8) | 27 (15.5) | 38 (27.0) | 10 (14.5) | 146 (11.7) | 5 (16.1) | 142 (26.7) | 236 (33.1) |
| Active Smoking | 143 (28.3) | 27 (19.1) | 26 (14.9) | 62 (44.0) | 8 (11.6) | -* | 7 (22.6) | 80 (15.0) | 139 (19.5) |
| Hypercholesterolemia | 148 (29.2) | 16 (11.3) | 37 (21.3) | 34 (24.1) | 4 (5.8) | 453 (36.2) | 8 (25.8) | 38 (7.1) | 258 (36.2) |
| Type of stroke |          |      |          |         |          |            |          |            |            |
| Ischemic     | 383 (75.7) | 99 (70.2) | 100 (57.5) | 105 (74.5) | 65 (94.2) | 888 (70.9) | 23 (74.2) | 402 (75.6) | 579 (81.2) |
| TIA          | 80 (15.8) | 28 (19.9) | 63 (36.2) | 14 (9.9) | 2 (2.9) | 298 (23.8) | 3 (9.7) | 1 (0.2) | 23 (3.8) |
|                      | Hemorrhagic | Acute treatment (ischemic stroke) | IV thrombolysis | Mechanical thrombectomy | Functional status (at discharge) | Death | Recurrence |
|----------------------|-------------|----------------------------------|-----------------|-------------------------|----------------------------------|-------|------------|
|                      | 43 (8.5)    | 14 (9.9)                          | 11 (6.3)        | 22 (15.6)               | 2 (2.9)                          | 66 (5.3)| 5 (16.1)   |
|                      |             | 129 (24.2)                        |                 |                         |                                  |       | 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 14 (9.9)    | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 11 (6.3)    | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 22 (15.6)   | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 2 (2.9)     | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 66 (5.3)    | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 5 (16.1)    | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 129 (24.2)  | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 111 (22.4)  | 129 (24.2)                        | 22 (15.6)       | 2 (2.9)                 | 66 (5.3)                         | 5 (16.1)| 129 (24.2) |
|                      |             | 111 (22.4)                        |                 |                         |                                  |       | 111 (22.4) |
|                      | 79 (15.6)   | 22 (15.6)                          | 1 (0.6)         | 7 (5.0)                 | 0 (0)                            | 22 (1.8)| 0 (0)      |
|                      |             | 37 (7.0)                           |                 |                         |                                  |       | 37 (7.0)   |
|                      |             | 32 (4.5)                           |                 |                         |                                  |       | 32 (4.5)   |
|                      | 22 (15.6)   | 22 (15.6)                          | 1 (0.6)         | 7 (5.0)                 | 0 (0)                            | 22 (1.8)| 0 (0)      |
|                      |             | 32 (4.5)                           |                 |                         |                                  |       | 32 (4.5)   |
|                      | 1 (0.7)     | 0 (0)                              |                 |                         |                                  |       | 1 (0.7)    |
|                      |             | 0 (0)                              |                 |                         |                                  |       | 0 (0)      |
|                      | 3 (9.7)     | 0 (0)                              |                 |                         |                                  |       | 3 (9.7)    |
|                      |             | 0 (0)                              |                 |                         |                                  |       | 0 (0)      |

* Not available at the dataset.